Cytarabine Hydrochloride for Injection

This product is a pyrimidine anti-metabolite drug that mainly acts on cells in the S proliferation phase. It interferes with cell proliferation by inhibiting the synthesis of cell DNA. After entering the human body, cytarabine is phosphorylated by kinase and converted into cytarabine triphosphate and cytarabine diphosphate. The former can strongly inhibit the synthesis of DNA polymerase, and the latter can inhibit the conversion of cytidine diphosphate to deoxycytidine diphosphate, thereby inhibiting cell DNA polymerization and synthesis. This product is a cell cycle-specific drug, which is most sensitive to cells in the S proliferation phase, and has a weaker effect on inhibiting RNA and protein synthesis.

The chemical name of this product is: 1-b-D-arabinofuranosyl-4-amino-2(1H)-pyrimidinone hydrochloride. Molecular formula: C9H13N3O5HCl Molecular weight: 279.68

This product is white loose mass or powder.

It is suitable for the induction remission and maintenance consolidation phases of acute leukemia. It has a better effect on acute non-lymphocytic leukemia, the blast crisis phase of chronic myeloid leukemia, and malignant lymphoma.

1 Common dosage for adults: (1) Induction of remission: intravenous injection or drip once per body weight of 2 mg/kg (or 1-3 mg/kg), once a day, for 10-14 days. If there is no obvious adverse reaction, the dose can be increased to 4-6 mg/kg per body weight; (2) Maintenance: After complete remission, the maintenance treatment dose is changed to 1 mg/kg per body weight, 1-2 times a day, subcutaneous injection, for 7-10 days. 2 Medium-dose cytarabine Medium-dose refers to a regimen of cytarabine with a dose of 0.5-1.0 g/m2 per body surface area, generally requiring intravenous drip for 1-3 hours, twice a day, with a course of 2-6 days; high-dose cytarabine is a regimen of 1-3 g/m2 per body surface area, and the intravenous drip and course of treatment are the same as the medium-dose regimen. Since the adverse reactions of cytarabine increase with increasing doses, which sometimes limit its efficacy, the medium-dose regimen is now more preferred. Medium or high doses of cytarabine are mainly used to treat refractory or recurrent acute leukemia, and can also be used to prolong the remission period after the remission of acute leukemia. Due to the large number of adverse reactions, the course of treatment must be guided by a doctor with rich experience, and sufficient and timely supportive therapy must be guaranteed before it can be carried out; 3 The dose of low-dose cytarabine is 10 mg/m2 per body surface area, subcutaneously injected twice a day, with a course of 14 to 21 days. If there is no remission and the patient's condition permits, a course of treatment can be repeated in 2 to 3 weeks. This regimen is mainly used to treat patients with increased primitive cells or myelodysplastic syndrome, and can also treat low-proliferative acute leukemia, elderly acute lymphocytic leukemia, etc.; 4 Intrathecal injection of cytarabine is the second-line drug for intrathecal injection to prevent and treat meningeal leukemia, with a dose of 25 to 75 mg once, combined with dexamethasone 5 mg, dissolved in 2 ml of 0.9% sodium chloride injection, intrathecal injection, 1 to 2 times a week, until the cerebrospinal fluid is normal. If it is for prevention, it should be taken once every 4 to 8 weeks. When using this product, the patient's fluid intake should be appropriately increased to keep the urine alkaline. If necessary, allopurinol should be used together to prevent increased serum uric acid and the formation of uric acid nephropathy. Although rapid intravenous injection causes more severe nausea and vomiting reactions, it has less suppression on the bone marrow, and patients can tolerate larger doses of cytarabine better.

1. Hematopoietic system: mainly bone marrow suppression, leukopenia and thrombocytopenia, severe cases may develop aplastic anemia or megaloblastic anemia; 2. Hyperuricemia may occur in patients with leukemia and lymphoma at the beginning of treatment, and uric acid nephropathy may occur in severe cases; 3. Less common symptoms include stomatitis, esophagitis, abnormal liver function, fever reaction and thrombophlebitis. Cytarabine syndrome usually occurs 6 to 12 hours after medication, with symptoms such as bone pain or myalgia, sore throat, fever, general discomfort, rash, and red eyes.

Not suitable for pregnant or lactating women.

Precautions for children: Not clear yet Precautions for pregnancy and lactation: Pregnant and lactating women should not use. Precautions for the elderly: As the elderly have poor tolerance to chemotherapy drugs, the dosage should be reduced and the dosage should be adjusted in time according to physical signs.

Tetrahydrouridine can inhibit deaminase, prolong the plasma half-life of cytarabine, increase the blood concentration, and play a synergistic role. This product can synchronize cells partially, and continued use of daunorubicin, doxorubicin, cyclophosphamide and nitrosourea drugs can enhance the effect. This product should not be used in combination with 5-Fm.

Keep away from light and tightly sealed in a cold place.

100mg

24 months

Han Hui Pharmaceuticals Company Limited

• Founded in:

  2012-09-06

• Address:

  No. 2 Haizheng Road, Xukou Town, Fuyang District, Hangzhou City, Zhejiang Province

• Tax NO.:

  91330100053653670B

• Registered Funds:

  1852.03035908 yuan

• Website:

  Log in to view

• Email:

  Log in to view